Quest Diagnostics (DGX) Capital Expenditures (2009 - 2026)

Quest Diagnostics (DGX) has 18 years of Capital Expenditures data on file, last reported at $114.0 million in Q1 2026.

• Quarterly Capital Expenditures fell 2.56% year-over-year to $114.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $524.0 million (up 19.63% YoY) and the FY2025 annual result came in at $527.0 million, up 24.0% from the prior year.
• Capital Expenditures retreated to $114.0 million in Q1 2026 per DGX's latest filing, from $158.0 million in the prior quarter.
• The five-year high for Capital Expenditures was $158.0 million in Q4 2025, with the low at $63.0 million in Q1 2022.
• Average Capital Expenditures over 5 years is $110.5 million, with a median of $108.0 million recorded in 2025.
• The widest YoY moves for Capital Expenditures: up 101.59% in 2023, down 51.02% in 2023.
• Quest Diagnostics' Capital Expenditures stood at $147.0 million in 2022, then sank by 51.02% to $72.0 million in 2023, then surged by 70.83% to $123.0 million in 2024, then advanced by 28.46% to $158.0 million in 2025, then decreased by 27.85% to $114.0 million in 2026.
• Business Quant data shows DGX's Capital Expenditures at $114.0 million in Q1 2026, $158.0 million in Q4 2025, and $144.0 million in Q3 2025.